Creo Medical Group (LON:CREO) Posts Earnings Results

Creo Medical Group (LON:CREO) posted its quarterly earnings data on Wednesday. The company reported GBX (2) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%.

Creo Medical Group Price Performance

CREO stock traded down GBX 0.13 during mid-day trading on Friday, hitting GBX 9.67. The stock had a trading volume of 2,207,440 shares, compared to its average volume of 794,158. The firm has a market capitalization of £46.96 million, a P/E ratio of 9.67 and a beta of 1.56. The company has a current ratio of 2.79, a quick ratio of 2.19 and a debt-to-equity ratio of 8.09. The firm has a fifty day simple moving average of GBX 12.54 and a 200 day simple moving average of GBX 12.80. Creo Medical Group has a 52 week low of GBX 9.50 and a 52 week high of GBX 18.50.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reissued a “house stock” rating and set a GBX 40 price target on shares of Creo Medical Group in a report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.